DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Reclast (Zoledronic Acid) - Summary

 


Nutrilib.com
A comprihensive source of nutritional information

RECLAST SUMMARY

Reclast contains zoledronic acid, a bisphosphonic acid which is an inhibitor of osteoclastic bone resorption.

Reclast (zoledronic acid) is indicated for the following:

Postmenopausal Osteoporosis

      Reclast is indicated for treatment of osteoporosis in postmenopausal women. In postmenopausal women with osteoporosis, Reclast reduces the incidence of fractures (hip, vertebral and non-vertebral osteoporosis-related fractures) [ see Clinical Studies (14 .1)].

Paget's Disease of Bone

Reclast is indicated for treatment of Paget's disease of bone in men and women. Treatment is indicated in patients with Paget’s disease of bone with elevations in serum alkaline phosphatase of two times or higher than the upper limit of the age-specific normal reference range, or those who are symptomatic, or those at risk for complications from their disease [ see Clinical Studies (14 . 2 ) ].


See all Reclast indications & dosage >>

RECLAST NEWS HIGHLIGHTS

Media Articles Related to Reclast (Zoledronic Acid)

Zoledronic Acid Protects Bones of Women Getting Breast Cancer Treatment
Source: MedicineNet tamoxifen Specialty [2008.08.20]

more >>

Published Studies Related to Reclast (Zoledronic Acid)

A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. [2008.10.01]

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. [2008.09]

Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases. [2008.06.03]

Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. [2008.05]

Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study. [2008.03.31]

more >>

Clinical Trials Related to Reclast (Zoledronic Acid)

Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy [Recruiting]

Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma [Recruiting]

Zometa and Circulating VEGF in Breast Cancer Patients With Bone Metastasis [Recruiting]

Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss [Recruiting]

Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year [Recruiting]

more >>

Page last updated: 2008-11-03

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008